stayonearth

www.annalsofoncology.org/article/S0923-7534(19)49908-0/fulltext Conclusions: JNJ-372 is a novel EGFR-cMET bispecific antibody with a manageable safety profile consistent with EGFR and cMET inhibition. Preliminary evidence suggests JNJ-372 can have activity in EGFR-driven NSCLC, including pts resistant to EGFR TKIs. 타그리소 내성에 대한 연구. 이 논문에 대한 우리나라 기사 www.medicaltimes.com/Users/News/NewsView.html?ID..

www.clinicaloptions.com/oncology/programs/egfr-tkis-sympo/downloadable-slideset/slideset1?origin=2 EGFR TKIs and EGFRmut NSCLC - Downloadable Slidesets - EGFR TKIs in NSCLC for Pharmacists In this slideset, Val R. Adams, PharmD, FCCP, BCOP, reviews the landscape of EGFR mutations in advanced NSCLC and the pharmacology of EGFR TKIs used in this setting. www.clinicaloptions.com 이 논문에는 비소세포폐암(NSCLC..

www.clinicaloptions.com/oncology/conference-coverage/clin-onc-2020/lung-cancer/capsule-summary-slidesets/9504?origin=1&utm_campaign=Oncology&utm_medium=email&_hsmi=88786798&_hsenc=p2ANqtz--ZswMOS6dLHtes2bZHMhKtrtHdMOl3tf5fV-_uVtY-Vmt0sdNEk2ievoKCRTU6deO_eS_2H03FNVJHzCSUuMe4bt4V7Q&utm_content=88786798&utm_source=hs_email DESTINY-Lung01 - Capsule Summary Slidesets - Lung Cancer - 2020 ASCO Annual ..